Tvardi director granted 6,000 stock options
Tvardi Therapeutics, Inc. director Hall Wallace Jr. received a grant of stock options covering 6,000 shares of common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Tvardi Therapeutics, Inc. director Hall Wallace Jr. received a grant of stock options covering 6,000 shares of common stock. The options have an exercise price of $2.78 per share and expire on June 8, 2036.
All 6,000 underlying shares will vest on the earlier of June 9, 2027 or the company’s next annual meeting of stockholders, as long as Wallace continues in service through that date. This is a compensation-related award rather than an open-market purchase or sale.
Insider Trade Summary
Grant/Award: 6,000 shares
Grant/Award
1 txn
Insider
HALL WALLACE L JR
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 6,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 6,000 contracts (Direct)
Footnotes (1)
- F1. 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
Key Figures
Options granted: 6,000 options
Exercise price: $2.78 per share
Expiration date: June 8, 2036
+3 more
6 metrics
Options granted
6,000 options
Stock Option (right to buy) grant to director
Exercise price
$2.78 per share
Exercise price of stock option grant
Expiration date
June 8, 2036
Option term end date
Underlying shares
6,000 shares
Common stock underlying the option
Shares after transaction
6,000 options
Total derivative securities following grant
Vesting date trigger
June 9, 2027
Full vesting if earlier than next annual meeting
Key Terms
Stock Option (right to buy), exercise price, expiration date, underlying security, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 2.7800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-08T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
underlying security financial
"underlying_security_title: Common Stock"
vest financial
"100% of the shares underlying the option shall vest on the earlier of June 9, 2027"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Tvardi Therapeutics (TVRD) director Hall Wallace Jr. report on this Form 4?
Hall Wallace Jr. reported receiving a grant of stock options for 6,000 shares of Tvardi Therapeutics common stock. The grant is compensation-related, not an open-market trade, and represents an acquisition of derivative securities rather than a direct stock purchase or sale.
What are the key terms of the Tvardi Therapeutics (TVRD) stock options granted?
The option covers 6,000 shares of common stock with an exercise price of $2.78 per share and an expiration date of June 8, 2036. These terms define how many shares can be acquired, at what price, and for how long.
When do the Tvardi Therapeutics (TVRD) options granted to Hall Wallace Jr. vest?
All 6,000 shares underlying the option vest 100% on the earlier of June 9, 2027 or the company’s next annual stockholder meeting. Vesting is conditioned on the director’s continuous service through the applicable vesting date, aligning the award with ongoing board service.
Is the Tvardi Therapeutics (TVRD) Form 4 transaction a market purchase or sale of stock?
No, the Form 4 reports a grant of stock options, not an open-market purchase or sale of common stock. The transaction is categorized as a grant or award acquisition, reflecting equity-based compensation rather than immediate buying or selling in the public market.
How many Tvardi Therapeutics (TVRD) derivative securities does Hall Wallace Jr. hold after this grant?
After the reported transaction, Hall Wallace Jr. holds 6,000 stock options related to Tvardi Therapeutics common stock. These options are a right to buy shares at $2.78 per share if exercised before their June 8, 2036 expiration, subject to vesting conditions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
